Skip to content
IFPMA Twitter
IFPMA LinkedIn
IFPMA Youtube
IFPMA Slideshare
IFPMA Flickr
IFPMA RSS
Search for:
Primary Menu
Who We Are
IFPMA in Brief
Our Governance and Leadership
Our Membership
Full Members
Associations
Companies
Affiliate Members
Our Experts
Join Us
Topics
News Center
News Releases
Blog
Global Health Matters
Science Matters
DG’s Column
Statements
Resources
Publications
News Releases
Statements
Position Papers
Publications
External Studies
Infographics
Event Highlights
Multimedia
Interviews
Videos
Slides
IFPMA Interactive Platforms
IFPMA COVID-19 Hub
Global Health Progress
50 Years of Global Health Progress
Events
Upcoming IFPMA Events
Geneva Pharma Forums
Assemblies
Other IFPMA Events
IFPMA in External Events
IFPMA Press Briefings
Past IFPMA Events
Geneva Pharma Forums
Assemblies
Other IFPMA Events
IFPMA in External Events
IFPMA Press Briefings
Partners
BCR
Inventing Medicines and Vaccines
Strengthening Regulatory Systems
Ethics and Business Integrity
Boosting Innovation and Access
Tackling Global health challenges
Climate change
Economic footprint
IP
Sustainable innovation
Value of innovation
spotlight
Value of innovation
African Medicines Agency
Biosimilars
Biotherapeutic medicines
Falsified medicines
Import testing
Pharmacovigilance
Quality, safety, and efficacy
Regulatory conferences
Regulatory system strengthening / Harmonization
Supply chain
The Africa Regulatory Network (ARN)
The ARN: Le réseau africain de réglementation pharmaceutique
spotlight
Pharmacovigilance
IFPMA Code of Practice (2019)
Our Ethos in Action
Our Ethos
Code eLearning Tool
IFPMA Notes for Guidance
IFPMA Complaint Operating Procedure
How to File a Code Complaint
Complaint Submission Form
Cases
Business Ethics for APEC SMEs Initiative
Consensus Framework for Ethical Collaboration
spotlight
IFPMA Code of Practice (2019)
Access to medicines
Global Policy Principles on Digital Health
Health technology assessment
IP
Technology Transfer
Trade
spotlight
Access to medicines
Ageing
Antimicrobial resistance
Cancer
Child and maternal health
COVID-19
Diabetes
Ebola
Falsified medicines
HIV/AIDS
Influenza
Malaria
Mental and neurological disorders
Neglected tropical diseases
Non-communicable diseases
Pandemic Preparedness
Public health implications of the implementation of the Nagoya Protocol
Rare diseases
Supply chain
Sustainable development goals
Tuberculosis
Universal Health Coverage
Vaccination confidence
Vaccines innovation
Vaccines protect communities
Vaccines sustainability
Value of immunization
Viral hepatitis
spotlight
Universal Health Coverage
Home
>
Tag: Global Health
Tag: Global Health
Innovative financing into hepatitis B and C prevention and treatment in low and middle income countries
Innovative sources of financing to help scale up prevention and treatment of viral hepatitis in low and middle-income countries
Health technology assessment
Value of immunization
Mental and neurological disorders addressing a global health priority
2015 IFPMA pharma by numbers - Video
IFPMA 2015 pharma by numbers
IFPMA facts & figures 2015
The Exciting Journey from Flu Virus to Vaccine
Evidence-informed benefits design in the context of universal health coverage, proposed policy principles
R&D pipeline for malaria
Pharmaceutical industry and global health
Pharma R&D and global health - IFPMA facts & figures 2014
Pharmaceutical R&D Projects to Prevent and Control Neglected Conditions
Technology transfer: a collaborative approach to improve global health
Innovation for a healthier world: How the research-based vaccine manufacturers are contributing to the Decade of vaccines action plan
Mr Masafumi Nogimori, speach at the closing session
Dr Stefan Oschmann, inaugural speech – transcript
Hepatitis C Infographic
WHA 67 agenda item 11.3, Framework of engagement with non-State actors
Agenda item 5, "WHO Reform"
WHA 66 agenda item 13.2 on draft action plan for the prevention and control
WHA 66, Item 16.2, Neglected tropical diseases
Health by the numbers: results of the 2011 IFPMA wellness survey
R&D-based pharmaceutical industry and International Federation of Red Cross and Red Crescent Societies join forces to prevent NCDs
Introducing the study "Falsified medicines and the global public's health"
Introduction - Mario Ottiglio, director, public affairs and global health policy, IFPMA
Fake medicines - imminent risks to global health
Fake medicines - Imminent risks to global health: remarks by Jamil Chade
IFPMA highlights benefits of incremental innovation for global health
1
2
Next »
Other Tags
Access
Access to antiretrovirals
Access to Medicines
Access to vaccines
Africa
AMR
AMR Industry Alliance
Anti-Counterfeit
Antibiotics
antimicrobial resistance
antivirals
Biosimilars
Biotherapeutic Medicines
Biotherapeutics
Cancer
Clinical Trials
Code of Practice
collaboration
Counterfeit Medicines
Counterfeits
COVID-19
COVID-19 vaccines
Dementia
Developing World
Diabetes
Economic footprint
Epidemics
Ethics
Event Highlights
Fake Medicines
Fakes
Falsified Medicines
Fight the Fakes
Flu
Global Health
global health security
harmonization
Health
Health Partnerships
HIV/AIDS
IFPMA
IFPMA Assembly
IFPMA Statement
Immunization
Incremental Innovation
Influenza
Infographic
Infographics
Innovation
Innovation ecosystem
Intellectual Property
IP
Malaria
MDGs
Medicines
Mental and Neurological Disorders
NCDs
Neglected Tropical Diseases
News Releases
Non-Communicable Diseases
Novel Coronavirus (COVID-19)
NTDs
pandemic
Pandemic Influenza
Pandemic preparedness
pandemics
partnership
Partnerships
Pharma
Pharmacovigilance
Position Paper
Prevention
Publications
Public Health
Quality
R&D
Regulatory
regulatory systems
Related Links
Research
Safety
SDGs
Seasonal Influenza
Statements
Supply chain
Sustainable Development Goals
Sustainable Innovation
trade
Treatments
Tuberculosis
UHC
Universal Health Coverage
Vaccine
Vaccines
Value of Innovation
Videos
WHA
WHO
WIPO
Women’s Cancers